A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma

A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma

Abstract MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with Ann Arbor stage III–IV diffuse large B-cell lymphoma (DLBCL), but their impact in limited stage (LS) I–II is unclear. Therefore, we assessed the impact of MYC-R on progression-free survival (PFS) and overall sur...

Full description

Bibliographic Details
Main Authors:	A. V. de Jonge, J. A. A. Bult, D. F. E. Karssing, M. Nijland, M. E. D. Chamuleau, M. Brink
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-01-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-023-00971-y

Similar Items

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
by: Mohammad Barouqa, et al.
Published: (2022-08-01)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
by: A. Ortuzar Pasalodos, et al.
Published: (2022-06-01)

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy
by: A. Vera de Jonge, et al.
Published: (2020-10-01)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements, Diffuse Large B-Cell Lymphoma with <i>MYC</i>-Rearrangement, and Diffuse Large B-Cell Lymphoma with <i>MYC</i>-Cluster Amplification
by: Masashi Miyaoka, et al.
Published: (2022-11-01)

A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications
by: Dima El-Sharkawi, et al.
Published: (2023-04-01)

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL
by: F. Morschhauser, et al.
Published: (2022-06-01)

MYC Immunohistochemistry Predicts MYC Rearrangements by FISH
by: Julum Nwanze, et al.
Published: (2017-09-01)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
by: A. Vera de Jonge, et al.
Published: (2023-05-01)

P120: Novel genomic rearrangement leading to MYC over expression in the genomic setting of a pseudo-triple-hit diffuse large B-cell lymphoma
by: Ramakrishna Koduru, et al.
Published: (2024-01-01)

Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning
by: Thomas E. Tavolara, et al.
Published: (2024-01-01)

Differentiated approach in the treatment of diffuse large B-cell lymphoma according to c-MYC and BCL2 status
by: R. K. Karakulov, et al.
Published: (2022-01-01)

P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ATTENUATED R-CHOP
by: Diana Al-Sarayfi, et al.
Published: (2023-08-01)

Prognostication of Primary Tumor Location in Early-Stage Nodal Diffuse Large B-Cell Lymphoma: An Analysis of the SEER Database
by: Yi Xia, et al.
Published: (2021-08-01)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
by: W. Mo, et al.
Published: (2022-06-01)

Advanced strategies for end-stage heart failure: combining regenerative approaches with LVAD, a new horizon?
by: Cheyenne eTseng, et al.
Published: (2015-04-01)

MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)
by: Maria Chiara Tisi, et al.
Published: (2019-12-01)

High‐grade B‐cell lymphoma with MYC and BCL2 rearrangements with abundant multinucleated giant tumor cells
by: Man Zhang, et al.
Published: (2023-05-01)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
by: Yanjie Wang, et al.
Published: (2023-09-01)

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
by: Diana Al-Sarayfi, et al.
Published: (2022-09-01)

Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation.
by: Haralambieva, E, et al.
Published: (2006)

The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
by: Lotteke J. Y. M. Ziel-Swier, et al.
Published: (2022-01-01)

Limited-stage diffuse large B-cell lymphoma: current management and challenges
by: Zhang, X-Y, et al.
Published: (2021)

Primary Nodal Unclassifiable CD20 Negative Diffuse Large B-cell Lymphoma With Dual and Gene Rearrangement: A Diagnostic Challenge
by: Ita Hadžisejdić, et al.
Published: (2023-01-01)

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
by: Johanna A. A. Bult, et al.
Published: (2023-09-01)

A digital method to interpret the C-MYC stain in diffuse large B cell lymphoma
by: Jayalakshmi Balakrishna, et al.
Published: (2022-01-01)

A DIGITAL METHOD TO INTERPRET THE C-MYC STAIN IN DIFFUSE LARGE B CELL LYMPHOMA
by: Jayalakshmi P. Balakrishna, et al.
Published: (2022-01-01)

Identification of MYC/BCL2 double-expressers lymphomas in diffuse large B cell lymphoma patients and association with their prognostic parameters and survival rates: a single centre experience
by: Ahmad, Aliza, et al.
Published: (2022)

An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts MYC rearrangements in large B‐cell lymphoma
by: Rolando García, et al.
Published: (2022-08-01)

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
by: Sherene Loi, et al.
Published: (2022-01-01)

Prognostic impact of immunohistochemical and molecular genetic markers in Diffuse Large B-cell lymphoma
by: E. V. Kharchenko, et al.
Published: (2019-12-01)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
by: R. Alonso Alonso, et al.
Published: (2022-06-01)

Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides
by: Gustavo Moreira Amorim, et al.
Published: (2018-10-01)

The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
by: Matias Mendeville, et al.
Published: (2022-10-01)

MAGNETIC RESONANCE IMAGING IN THE STAGING OF MALIGNANT LYMPHOMAS
by: A. I. Mikhaylov, et al.
Published: (2016-02-01)

Association of pSTAT3, pSyk with c-Myc, p53, BCL2 proteins expression and survival of patients with diffuse large B-cell lymphoma
by: V. A. Rosin, et al.
Published: (2022-04-01)

Whole-Body Diffusion-Weighted Magnetic Resonance Imaging and Positron Emission Tomography Combined with Computed Tomography in the Staging of Lymphomas
by: S. A. Kharuzhyk, et al.
Published: (2020-01-01)

P1093: A NEW PROGNOSTIC MODEL FOR INDIVIDUAL OUTCOME PREDICTION IN ADVANCED-STAGE HODGKIN LYMPHOMA.
by: R. Rask Kragh Jørgensen, et al.
Published: (2022-06-01)

BCL-2 GENE REARRANGEMENT AND PROTEIN EXPRESSION IN PRIMARY CUTANEOUS B-CELL LYMPHOMAS
by: Pezzella, F, et al.
Published: (1994)

Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas
by: Stefano A. Pileri, et al.
Published: (2021-03-01)

PROGNOSTIC VALUE OF pSTAT3 EXPRESSION IN DIFFUSIVE B-LARGE CELL LYMPHOMA IN THE RUSSIAN PATIENT SAMPLE
by: E. V. Vaneeva, et al.
Published: (2019-11-01)